Table 1. Efficacy of erlotinib in 261 lung adenocarcinoma patients without detectable EGFR mutations at initial molecular testing.
| Best Response | |
| Patient No. (%) | |
| Complete response (CR) | 0 (0) |
| Partial response (PR) | 38 (14.6) |
| Objective response rate | 38 (14.6) |
| (ORR = CR + PR) | |
| Stable disease (SD) | 52 (19.9) |
| Disease control rate | 90 (34.5) |
| (DCR = CR + PR + SD) | |
| Progressive disease (PD) | 171 (65.5) |
PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; DC, disease control; PD, progressive disease.
a
38 patients are still under erlotinib treatment without PD.
b
102 patients are still alive.